Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $607,830.30 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 10,290 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $59.07, for a total value of $607,830.30. Following the sale, the senior vice president directly owned 16,406 shares of the company’s stock, valued at $969,102.42. The trade was a 38.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, March 16th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The shares were sold at an average price of $41.30, for a total transaction of $16,313.50.

Oruka Therapeutics Trading Up 5.5%

Shares of Oruka Therapeutics stock opened at $60.67 on Thursday. The firm has a fifty day simple moving average of $56.70 and a 200-day simple moving average of $40.07. Oruka Therapeutics, Inc. has a 1-year low of $10.26 and a 1-year high of $91.00. The stock has a market capitalization of $3.66 billion, a price-to-earnings ratio of -31.27 and a beta of -0.20.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.04. As a group, research analysts predict that Oruka Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Hedge Funds Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Remedium Capital Partners LLC lifted its position in shares of Oruka Therapeutics by 0.9% in the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock worth $76,796,000 after acquiring an additional 13,247 shares during the period. Royal Bank of Canada increased its position in shares of Oruka Therapeutics by 178.5% during the first quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock valued at $155,000 after purchasing an additional 2,033 shares during the period. Rock Springs Capital Management LP acquired a new position in shares of Oruka Therapeutics in the first quarter valued at $202,000. The Manufacturers Life Insurance Company lifted its position in Oruka Therapeutics by 18.3% in the first quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock worth $3,559,000 after purchasing an additional 11,205 shares during the period. Finally, Quantinno Capital Management LP bought a new position in Oruka Therapeutics in the first quarter worth $254,000. 56.44% of the stock is currently owned by institutional investors.

More Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates across several periods for Oruka Therapeutics, including FY2026 and FY2027, while reiterating a Buy rating and a $120 price target. The updated forecasts suggest analysts see improving loss trends and continued execution. Oruka Therapeutics analyst note
• Positive Sentiment: The company’s latest quarterly results also came in ahead of expectations, with Oruka reporting ($0.48) EPS versus the ($0.52) consensus estimate, which may be supporting sentiment around the stock. Oruka Therapeutics earnings beat
• Neutral Sentiment: HC Wainwright’s revisions still point to ongoing losses over the next several quarters, so the company remains a development-stage biotech with no near-term profitability expected.
• Negative Sentiment: Recent insider selling by SVP Arjun Agarwal may weigh on sentiment somewhat, although the sale was made under a pre-arranged 10b5-1 trading plan and does not necessarily signal a change in outlook. Insider sale report

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ORKA. Leerink Partners set a $120.00 price objective on Oruka Therapeutics in a research note on Thursday, April 30th. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 16th. Guggenheim set a $200.00 price target on Oruka Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 27th. Barclays upped their price target on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, April 27th. Finally, UBS Group increased their price objective on Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $120.80.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.